Company attributes
Other attributes
Based in Stockholm, Procella Therapeutics is an early stage biotechnology company focused on developing cardiac stem cell technology leveraging research from Harvard University and Karolinska Institutet with the aim of treating heart failure. Procella is collaborating with AstraZeneca to take our first cellular product candidate from pre-clinical stage to first-in-human studies and, if successful in early trials, further development towards commercial manufacture.
Procella Therapeutics started in 2018 upon a vision to create the next generation of cell-based therapies for patients running out of options.
Our first mission is to develop a cardiac stem cell therapy for patients with advance heart failure and to do this with focus, drive, persistence, creativity, integrity, and inclusiveness.
